Pulsed Field Ablation Outcomes in Atrial Fibrillation: Randomized Comparison to Traditional Ablation
Official title: Pulsed Field Ablation for Atrial Fibrillation Including Posterior Wall and Linear Ablation: A Randomized Controlled Trial of Safety and Efficacy (POWER-AF)
Run by China National Center for Cardiovascular Diseases · NCT07601763 · Data updated 2026-11-12
This study tests pulsed field ablation versus conventional radiofrequency ablation in adults with atrial fibrillation to see which method better preserves heart rhythm.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1574 (estimated) |
| Sponsor | China National Center for Cardiovascular Diseases Government |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | April 16, 2025 |
| Main results expected | November 30, 2027 |
| Study ends | November 30, 2028 |
| Registry record updated | May 28, 2026 |
| Trial ID | NCT07601763 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with atrial fibrillation who are suitable for catheter ablation and can provide informed consent.
✕Probably not a fit
Patients with contraindications to ablation or previous ablation, recent cardiac events, or other exclusion criteria may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional trial compares pulsed field ablation (PFA) with radiofrequency ablation (RFA) for treating atrial fibrillation in adults. Participants undergo either PFA or RFA to determine safety and effectiveness in maintaining sinus rhythm. The study utilizes predefined criteria to enroll eligible patients and excludes those with recent cardiac events or contraindications to ablation. Outcomes will inform whether the novel PFA approach offers advantages over traditional energy delivery. The trial is conducted under the banner of the China National Center for Cardiovascular Diseases at Fuwai Hospital.
Why it matters
Potential benefit: If successful, patients may experience better rhythm control and fewer procedure-related complications with pulsed field ablation.
How similar studies have gone: Previous studies have demonstrated the effectiveness of catheter ablation for AF, but the relative advantages of pulsed field ablation require further confirmation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Atrial fibrillation patients who will accept catheter ablation. 2. Age ≥ 18. 3. Be capable of understanding and signing the informed consent form. Exclusion Criteria: 1. Have contraindications for catheter ablation (such as atrial thrombosis, decompensated heart failure, etc.) 2. Have accepted catheter ablation before. 3. Myocardial infarction, or any cardiac interventional/surgery has been performed within 3 months. 4. Had a stroke or transient ischemic attack within 6 months. 5. Allergy to iodine contrast agents. 6. Participate in clinical trials related to other drugs or devices. 7. Pregnant women, lactating women, or women with plans to become pregnant shortly. 8. Active stage of infection. 9. Secondary atrial fibrillation, such as combined with rheumatic heart disease, hypertrophic cardiomyopathy, etc. 10. Patients who do not agree to be enrolled or are unable to cooperate to complete the study
Where it's running
-
National Cardiovascular Diseases Center, Fuwai Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Yan Yao
- Email: ianyao@263.net.cn
- Phone: 010-88392405
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Electroporation versus Radiofrequency Ablation Guided by 3D Imaging for Repeat Atrial Fibrillation
This trial tests whether pulsed field electroporation or standard radiofrequency ablation works better and safer for people having a repeat catheter ablation for recurrent atrial fibrillation.
-
Comparing FARAPULSE and FARAWAVE Nav catheters during pulmonary vein isolation for atrial fibrillation
This test will see if the FARAWAVE Nav catheter's built-in mapping can be used instead of pre-procedure CT scans for adults having pulmonary vein isolation for atrial fibrillation.
-
Factors Linked to Slow Heart Rate After Pulsed Field Ablation for Atrial Fibrillation
This study looks for factors that might cause bradycardia during the hospital stay after AF ablation using pulsed field technology.
-
Very high-power short-duration vs standard low-power radiofrequency ablation for atrial fibrillation
This trial tests whether very high-power short-duration ablation (90 W) is as safe and more effective than conventional low-power ablation (35-45 W) for treating atrial fibrillation.
-
BDNF Levels and Atrial Cardiomyopathy in People Having AF Ablation
This study tests whether circulating BDNF levels are linked to atrial cardiomyopathy in adults having their first ablation for persistent atrial fibrillation.
-
Catheter ablation vs optimized medical care for very elderly with atrial fibrillation
In people aged 78 and up with AF, this study tests whether catheter ablation can help by comparing it to tailored medical therapy, using a wearable rhythm monitor to track AF over time.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.